Publication: Extracellular DNA traps released by acute promyelocytic leukemia cells through autophagy
Open/View Files
Date
2016
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Nature Publishing Group
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Ma, R., T. Li, M. Cao, Y. Si, X. Wu, L. Zhao, Z. Yao, et al. 2016. “Extracellular DNA traps released by acute promyelocytic leukemia cells through autophagy.” Cell Death & Disease 7 (6): e2283. doi:10.1038/cddis.2016.186. http://dx.doi.org/10.1038/cddis.2016.186.
Research Data
Abstract
Acute promyelocytic leukemia (APL) cells exhibit disrupted regulation of cell death and differentiation, and therefore the fate of these leukemic cells is unclear. Here, we provide the first evidence that a small percentage of APL cells undergo a novel cell death pathway by releasing extracellular DNA traps (ETs) in untreated patients. Both APL and NB4 cells stimulated with APL serum had nuclear budding of vesicles filled with chromatin that leaked to the extracellular space when nuclear and cell membranes ruptured. Using immunofluorescence, we found that NB4 cells undergoing ETosis extruded lattice-like structures with a DNA–histone backbone. During all-trans retinoic acid (ATRA)-induced cell differentiation, a subset of NB4 cells underwent ETosis at days 1 and 3 of treatment. The levels of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) were significantly elevated at 3 days, and combined treatment with TNF-α and IL-6 stimulated NB4 cells to release ETs. Furthermore, inhibition of autophagy by pharmacological inhibitors or by small interfering RNA against Atg7 attenuated LC3 autophagy formation and significantly decreased ET generation. Our results identify a previously unrecognized mechanism for death in promyelocytes and suggest that ATRA may accelerate ET release through increased cytokines and autophagosome formation. Targeting this cellular death pathway in addition to conventional chemotherapy may provide new therapeutic modalities for APL.
Description
Other Available Sources
Keywords
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service